Confidence in Concept 2012 - University of Manchester

Lead Research Organisation: University of Manchester

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Technical Summary

The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding.  It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.

Publications

10 25 50

publication icon
Cheng A (2014) Cartilage repair using human embryonic stem cell-derived chondroprogenitors. in Stem cells translational medicine

publication icon
Mohamed TM (2013) Optimisation and validation of a high throughput screening compatible assay to identify inhibitors of the plasma membrane calcium ATPase pump--a novel therapeutic target for contraception and malaria. in Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques

publication icon
Payton A (2016) A role for HLA-DRB1*1101 and DRB1*0801 in cognitive ability and its decline with age. in American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics

 
Description MRC Regenerative Medicine Board funding to Professor Susan Kimber
Amount £793,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 01/2014 
End 01/2017
 
Description University of Manchester Intellectual Property PoP award to Professor Paul Bishop
Amount £20,589 (GBP)
Organisation University of Manchester 
Department Intellectual Property
Sector Academic/University
Country United Kingdom
Start 10/2014 
End 01/2015
 
Description Collaboration between Elizabeth Cartwright and MRCT 
Organisation MRC-Technology
Country United Kingdom 
Sector Academic/University 
PI Contribution Scientific validation of hypothesis for PMCA4 as a novel target for treatment of cardiac hypertrophy and heart failure. Optimisation and validation of a high throughput screening compatible assay for the sarcolemmal calcium ATPase pump and initial studies on discovery of new inhibitors.
Collaborator Contribution MRCT have put in place a team to work with us including a project manager, medicinal chemists and a business development manager. Over the next 6 months MRCT will fund additional library screening and assay development.
Impact Collaboration ongoing, no outcomes reported yet.
Start Year 2014
 
Description Collaboration between Neil Pendleton and group led by Professor Harold Garner, Virginia Technology Institute 
Organisation Virginia Tech
Country United States 
Sector Academic/University 
PI Contribution DNA to be sent to the USA for in depth analysis that will have both significant consequences in the short term for our project but a key component for future applications.
Collaborator Contribution Analysis of variable number tandem repeats (VNTRs) as part of the NIH 10K genome project. These VNTRs are a major component of the two human specific domains we have analysed in this proposal.
Impact Collaboration ongoing and outputs not yet reported. Expectation that data generated will be used as the basis for future grant applications.
Start Year 2014
 
Description Collaboration between Professor Ian Roberts and Bluestone Global Tech 
Organisation Bluestone Global Tech
Country United States 
Sector Private 
PI Contribution Development, optimisation and standardisation of a GO preparation and purification method from commercially produced Graphite Oxide.
Collaborator Contribution Bluestone Global Tech acts as a collaborator in this project manufacturing Graphite Oxide and other materials and providing technical assistance for different aspects of the project.
Impact Ability to control production of GO with flakes of desired lateral size (0.5-15µm). This is a significant achievement allowing reproducible experiments to be undertaken for the first time in this area.
Start Year 2014
 
Description Collaboration between Professor Jian Liu and 2D-Tech Ltd on Graphene Biomaterials 
Organisation 2-DTech
Country United Kingdom 
Sector Private 
PI Contribution Extensive knowledge and expertise in surfactant science and biointerface, enabling optimisation of schemes for batch production of reproducible G and GO samples as aqueous dispersions with excess surfactants removed. This approach opens up further capability for making biocompatible polymeric G and GO composites.
Collaborator Contribution 2D-Tech Ltd is a spin out company of the University of Manchester that has expertise in applications of graphene research and collaborated with the investigator on the G/GO sample production.
Impact Progress in preparation of biocompatible polymeric G and GO nanocomposites. Expectation of application to EPSRC and BBSRC for further grant supports, with 2D-Tech as collaborator
Start Year 2013
 
Company Name Opticin Limited 
Description The Bishop lab discovered a molecule in the vitreous humour of the eye that they called opticin. Subsequent work demonstrated that opticin has potent anti-angiogenic properties and contributes to the avascular state of the vitreous. This work has been patented. They subsequently found that smaller fragments of the opticin molecule demonstrated anti-angiogenic properties using in vitro assays. This work, along with previous data on the intact opticin molecule, has led to the formation of a spin-out company called Opticin Limited in July 2014. 
Year Established 2014 
Impact The results of this research have been kept confidential. It is anticipated that a new patent will be filed once the design of the peptide/peptidomimetic has been optimised.